Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zicam Case Shows FDA Takes Defining Adverse Events Seriously

This article was originally published in The Tan Sheet

Executive Summary

Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products

Related Content

Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies
Trade Groups Back Matrixx On AER Disclosure In Supreme Court Case
FDA Warns In Recall Guidance Agency Has Arsenal Of Enforcement Options
Zicam Swab Platform Takes Center Stage In Matrixx Growth Plans
Attention To Details Helps Firms Conduct "Short And Sharp" Recalls - Experts
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
FDA's "Act Now" Philosophy Has Drawbacks For Industry - CHPA Exec
People In Brief
Matrixx Must Transition Zicam Customers To Oral Products As Options Narrow





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts